Apogee Therapeutics, Inc. financial data

Symbol
APGE on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1658% % -32%
Return On Assets -37% % -76%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 59,315,738 shares 4.2%
Entity Public Float $1,433,600,000 USD
Common Stock, Value, Issued $1,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 58,773,731 shares 3.5%
Weighted Average Number of Shares Outstanding, Diluted 58,773,731 shares 3.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $216,497,000 USD 59%
General and Administrative Expense $66,923,000 USD 61%
Operating Income (Loss) $283,420,000 USD -59%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $253,440,000 USD -33%
Income Tax Expense (Benefit) $234,000 USD
Net Income (Loss) Attributable to Parent $253,674,000 USD -73%
Earnings Per Share, Basic -4 USD/shares -428%
Earnings Per Share, Diluted -4 USD/shares -428%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $107,914,000 USD -9.1%
Marketable Securities, Current $419,375,000 USD 3%
Other Assets, Current $919,000 USD 132%
Assets, Current $540,097,000 USD 1%
Property, Plant and Equipment, Net $6,032,000 USD 326%
Operating Lease, Right-of-Use Asset $9,646,000 USD -20%
Other Assets, Noncurrent $8,744,000 USD 1601%
Assets $626,159,000 USD -19%
Accounts Payable, Current $376,000 USD -83%
Employee-related Liabilities, Current $12,682,000 USD 83%
Accrued Liabilities, Current $29,592,000 USD 7.5%
Liabilities, Current $34,047,000 USD 4.4%
Operating Lease, Liability, Noncurrent $5,774,000 USD -38%
Liabilities $39,821,000 USD -4.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,028,000 USD -69%
Retained Earnings (Accumulated Deficit) $492,372,000 USD -106%
Liabilities and Equity $626,159,000 USD -19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $48,477,000 USD -53%
Net Cash Provided by (Used in) Financing Activities $450,520,000 USD
Net Cash Provided by (Used in) Investing Activities $12,982,000 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 60,147,727 shares 2.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $34,873,000 USD -109%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $107,914,000 USD -9.4%
Deferred Tax Assets, Valuation Allowance $76,083,000 USD 152%
Deferred Tax Assets, Gross $78,838,000 USD 156%
Operating Lease, Liability $11,831,000 USD 492%
Depreciation $400,000 USD
Payments to Acquire Property, Plant, and Equipment $4,317,000 USD 1130%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $255,916,000 USD -78%
Lessee, Operating Lease, Liability, to be Paid $13,161,000 USD 496%
Operating Lease, Liability, Current $4,079,000 USD 42%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,475,000 USD 260%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,909,000 USD 214%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure -10%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,330,000 USD 664%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,049,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $16,095,000 USD 200%
Unrecognized Tax Benefits $3,603,000 USD 299%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,110,000 USD
Additional Paid in Capital $1,077,681,000 USD 11%
Share-based Payment Arrangement, Expense $41,956,000 USD 134%